Acupuncture in the Regulation of Dai Meridian for Polycystic Ovarian Syndrome Patients With Abdominal Obesity

September 11, 2017 updated by: Hui Hu, Dongfang Hospital Beijing University of Chinese Medicine
The purpose of this study is to determine whether the use of electroacupuncture to dredge and regulate Dai Meridian combined with lifestyle modification are more effective than lifestyle modification only in the treatment of anovulation and hyperandrogenism due to polycystic ovary syndrome (PCOS) with abdominal obesity.Two thirds of participants will receive electroacupuncture and lifestyle modification in combination, while the other one third will receive lifestyle modification only.

Study Overview

Detailed Description

Obesity, especially abdominal obesity, is one of most common clinical features of polycystic ovary syndrome, a widely and seriously influenced complex disorder related to reproduction and metabolism. Excessive accumulation of adipose tissue in the abdominal organs often leads to insulin resistance, which will increase the harm of hyperandrogenism and exacerbate ovulation disorders and metabolic abnormalities.

Weight loss, likely beneficial for both reproductive and metabolic dysfunction in this setting , has been generally recommended as a first-line therapy for obese women with PCOS and can be accomplished via lifestyle modification and electroacupuncture. What's more, stimulating acupoints of Dai Meridian can regulate menstrual cycles and treat infertility according to the theory of traditional Chinese medicine. However, how much benefits patients will additionally get from the Combined therapy is not clear now.

Study Type

Interventional

Enrollment (Anticipated)

84

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beijing
      • Beijing, Beijing, China, 100078
        • Department of Acupuncture and Moxibustion, Dongfang Hospital, Beijing University of Chinese Medicine
      • Beijing, Beijing, China, 100078
        • Dongfang Hospital Affiliated to Beijing University of Chinese

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 36 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Clinical diagnosis of Polycystic Ovarian Syndrome.
  • Clinical diagnosis of abdominal obesity.
  • Agree to participate in clinical trials.

Exclusion Criteria:

  • Endocrine or neoplastic causes of amenorrhoea, anovulation and hyperandrogenemia, including central nervous system abnormalities, premature ovarian failure, thyroid disease, Cushing's syndrome,androgen secreting tumors, congenital adrenal hyperplasia, and hyperprolactinaemia.
  • Patients suffering from other serious diseases(cardiocerebrovascular diseases, damage to the function of liver and kidney, and mental illness).
  • Patients taking hormonal and metabolic drugs within 12 weeks of study entry affecting the judgment of results.
  • Pregnant or breast feeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: acupuncture & lifestyle modification
Electro-acupuncture is given three times a week with diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks.
Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.
The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
Active Comparator: lifestyle modification
diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks
The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
rate of recovered ovulation
Time Frame: 12 weeks
the proportion of patients who have ovulation after treatment
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
evidence of clinically definite hyperandrogenism confirmed by mF-G score
Time Frame: 12 weeks
12 weeks
evidence of clinically definite hyperandrogenism confirmed by the Global Acne Grading System
Time Frame: 12 weeks
12 weeks
frequency of menstruation
Time Frame: 12 weeks
12 weeks
quantity of menstruation
Time Frame: 12 weeks
pictorial blood loss assessment chart
12 weeks
Serum total testosterone (T)
Time Frame: 12 weeks
12 weeks
FSH
Time Frame: 12 weeks
follicle stimulating hormone (FSH)
12 weeks
LH
Time Frame: 12 weeks
luteinizing hormone (LH)
12 weeks
ovarian volume measured by ultrasound
Time Frame: 12 weeks
12 weeks
follicle number pre ovary measured by ultrasound
Time Frame: 12 weeks
12 weeks
ovarian stromal blood flow measured by ultrasound
Time Frame: 12 weeks
12 weeks
body weight in kilograms
Time Frame: 4, 8 and 12 weeks
4, 8 and 12 weeks
waist circumference in centimeter
Time Frame: 4, 8 and 12 weeks
4, 8 and 12 weeks
BMI in kg/m^2
Time Frame: 4, 8 and 12 weeks
4, 8 and 12 weeks
waist-to-height ratio
Time Frame: 4, 8 and 12 weeks
waist-to-height ratio=waist circumference in centimeter/height in centimeter
4, 8 and 12 weeks
Fasting serum PAI-1 level
Time Frame: 12 weeks
12 weeks
International physical activity scale (IPAQ) short version
Time Frame: 4, 8 and 12 weeks
4, 8 and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hui HU, Doctor, Dongfang Hospital Beijing University of Chinese Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2016

Primary Completion (Anticipated)

January 1, 2019

Study Completion (Anticipated)

September 1, 2019

Study Registration Dates

First Submitted

May 23, 2016

First Submitted That Met QC Criteria

May 25, 2016

First Posted (Estimate)

May 30, 2016

Study Record Updates

Last Update Posted (Actual)

September 12, 2017

Last Update Submitted That Met QC Criteria

September 11, 2017

Last Verified

September 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Polycystic Ovarian Syndrome

Clinical Trials on electroacupuncture

Subscribe